In Senior Adults Treated with Basal Insulin, Switching to Sanofi’s Toujeo® Halved Hypoglycemia Risk

Jun 10, 2017 - (Newswire)

- Sanofi announced today new evidence from a real-world observational study demonstrating significantly less risk of documented hypoglycemia with similar blood sugar control after switching to Toujeo® (insulin glargine 300 Units/mL) compared to switching to another basal insulin including Lantus® (insulin glargine 100 Units/mL), Levemir® (insulin detemir) and Tresiba® (insulin degludec), in an at-risk population of senior adults (aged ≥65 years) with type 2 diabetes. The results of the DELIVER 3 retrospective observational study comparing two cohorts were presented at the American Diabetes Association (ADA) 77th Scientific Sessions Annual Meeting in San Diego, CA, U.S.

In the DELIVER 3 study,1 patients switching to Toujeo were 57 percent less likely to experience hypoglycemia at 6-month follow-up (Odds Ratio: 0.432, 95% CI: 0.307 to 0.607, p

Original Source: https://www.newswire.com/news/in-senior-adults-treated-with-basal-insulin-switching-to-sanofis-toujeo-halved

What Next?

Related Articles

Leave a Reply

Submit Comment